Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 20404000)

1.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

2.

Two good choices to prevent breast cancer: great taste, less filling.

Hortobagyi GN, Brown PH.

Cancer Prev Res (Phila). 2010 Jun;3(6):681-5. doi: 10.1158/1940-6207.CAPR-10-0101.

3.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
4.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

5.

Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).

Cuzick J.

Cancer Prev Res (Phila). 2010 Jun;3(6):689-91. doi: 10.1158/1940-6207.CAPR-10-0096.

6.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
7.

Tamoxifen, raloxifene and the prevention of breast cancer.

Bentrem DJ, Craig Jordan V.

Minerva Endocrinol. 2002 Jun;27(2):127-39. Review.

PMID:
11961504
8.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
9.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

PMID:
20956826
10.

Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Nelson HD, Smith ME, Griffin JC, Fu R.

Ann Intern Med. 2013 Apr 16;158(8):604-14. doi: 10.7326/0003-4819-158-8-201304160-00005. Review.

PMID:
23588749
11.

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA.

JAMA. 2006 Jun 21;295(23):2742-51. Epub 2006 Jun 5. Erratum in: JAMA. 2007 Sep 5;298(9):973.

PMID:
16754728
12.

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N.

Clin Breast Cancer. 2002 Jun;3(2):153-9.

PMID:
12123540
13.

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

Jordan VC, Gapstur S, Morrow M.

J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review.

14.

[Additional effect of SERM: mammary gland].

Kurebayashi J.

Clin Calcium. 2004 Oct;14(10):47-51. Review. Japanese.

PMID:
15577131
15.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

16.

Chemoprevention of breast cancer.

O'Regan RM.

Cancer Treat Res. 2000;103:183-207. Review. No abstract available.

PMID:
10948447
17.

Selective estrogen-receptor modulators in 2001.

O'Regan RM, Gradishar WJ.

Oncology (Williston Park). 2001 Sep;15(9):1177-85, 1189-90; discussion 1190-4.

18.
19.

Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).

Lo SS, Vogel VG.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):97-111. Review.

PMID:
14687600
20.

Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.

Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L.

Ann Intern Med. 2009 Nov 17;151(10):703-15, W-226-35. doi: 10.7326/0003-4819-151-10-200911170-00147. Review.

PMID:
19920271
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk